Literature DB >> 7913037

Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection.

Y Zhang1, R Yasumizu, K Sugiura, F Hashimoto, Y Amoh, Z Lian, N Nishio, S Ikehara.   

Abstract

In this report we examine the fate of donor cells injected via different routes. When PKH-26-labeled C57BL/6 (B6) spleen cells were intravenously (i.v.) injected into BALB/c mice, the donor cells were rejected within 3 days. In contrast, when the same B6 spleen cells were portal venously (p.v.) injected, they were trapped in the recipient liver. When allogeneic or syngeneic whole bone marrow cells (BMC) or cells in a hemopoietic stem cell (HSC)-enriched fraction were either i.v. or p.v. injected, the cells accumulated in the liver. The cells trapped in the liver were found to be wheat germ agglutinin (WGA)-positive HSC. When B6 thymocytes were p.v. or i.v. injected into BALB/c mice, they were rapidly rejected. When BALB/c mice were i.v. preimmunized with unlabeled B6 spleen cells, BMC or thymocytes, the p.v. or i.v. injected PKH-26-labeled B6 spleen cells were rejected rapidly (within 2 days). In contrast, when BALB/c mice were p.v. preimmunized with B6 spleen cells or BMC, the p.v. or i.v. injected PKH-26-labeled B6 spleen cells were not rejected. The cells responsible for the tolerance induction were found to be HSC trapped in the liver. Delayed-type hypersensitivity assays revealed that the tolerance could be maintained for more than 49 days by p.v. injection plus i.v. injection (at intervals of 2 weeks) of HSC. These findings indicate that HSC trapped in the liver play a crucial role in the induction and maintenance of p.v. tolerance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913037     DOI: 10.1002/eji.1830240716

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

Review 1.  New strategies for BMT and organ transplantation.

Authors:  Susumu Ikehara
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis.

Authors:  Y Ohta; M Yamane; T Sohda; H Makino
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

3.  Simultaneous administration of a low-dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long-term survival of cardiac allograft in rats.

Authors:  Yongzhu Jin; Qingyin Zhang; Jie Hao; Xiang Gao; Yinglu Guo; Shusheng Xie
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

4.  A strategy for organ allografts without using immunosuppressants or irradiation.

Authors:  H Morita; K Sugiura; M Inaba; T Jin; J Ishikawa; Z Lian; Y Adachi; S Sogo; K Yamanishi; H Taki; M Adachi; T Noumi; Y Kamiyama; R A Good; S Ikehara
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

5.  Bone marrow transplantation reverses new-onset immunoinflammatory diabetes in a mouse model.

Authors:  Cheng-Lan Lv; Jing Wang; Ting Xie; Jian Ouyang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

6.  Comparison of the effect of bone marrow cells infusion through the portal vein and inferior vena cava combined with short-term rapamycin on allogeneic islet grafts in diabetic rats.

Authors:  Qingzhen Gao; Xiaoping Wang; Ruibin Zhang; Pu Wang; Yongsheng Jing; Wanjun Ren; Bin Zhu
Journal:  J Diabetes Investig       Date:  2016-01-23       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.